Compare VNDA & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VNDA | HRZN |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.0M | 265.5M |
| IPO Year | 2005 | 2010 |
| Metric | VNDA | HRZN |
|---|---|---|
| Price | $3.99 | $3.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $11.50 | $4.71 |
| AVG Volume (30 Days) | ★ 1.3M | 507.8K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 19.15% |
| EPS Growth | N/A | ★ 62.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $216,105,000.00 | N/A |
| Revenue This Year | $12.05 | $0.10 |
| Revenue Next Year | $30.61 | $17.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.72 | N/A |
| 52 Week Low | $3.57 | $3.70 |
| 52 Week High | $9.91 | $6.78 |
| Indicator | VNDA | HRZN |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 31.65 |
| Support Level | $3.57 | N/A |
| Resistance Level | $5.49 | $4.75 |
| Average True Range (ATR) | 0.28 | 0.17 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 34.42 | 12.44 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.